# Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

> **NCT02973477** · PHASE4 · COMPLETED · sponsor: **University of Michigan** · enrollment: 45 (actual)

## Conditions studied

- Type2 Diabetes
- Cardiovascular Diseases

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT02973477
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-12
- **Primary completion:** 2019-08-22
- **Final completion:** 2019-08-22
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02973477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02973477, "Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02973477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*